Similar organisations to Abetalipoproteinemia and Related Disorders Foundation
-
Epilepsy
-
1495.
Blue Cure Foundation
The Blue Cure Foundation's mission is to save lives through raising awareness of pro St ate cancer among all adult men Lifestyle choices for better health outcomes.
Houston
-
Education N.E.C.
-
1496.
Spinal Muscular Atrophy Foundation
The mission of the Spinal Muscular Atrophy Foundation is to accelerate the development of a treatment for SMA, the number one genetic killer of infants and toddlers.
-
Community Coalitions
-
1497.
BELAIR-EDISON HEALTHY COMMUNITY COALITION INC
Healthy Communities Coalition (HCC) convenes residents, community partners and researchers to share, learn and plan to improve community health.
Chicago
CHILDREN OBESITY FOUNDATION INC
HELP FIGHT THE OBESITY EPIDEMIC. LIFESTYLE MODIFICATION COURSE FOR LIFESTYLE FACILITATORS Lifestyle Modification Facilitator / Ambassador will understand and be comfortable to educate families, and children in the following key aspects of lifestyle modification: 1.
Boca Raton
-
Alliance/Advocacy Organizations
-
1499.
Nrxn1 Network
Our mission is to build a collaborative network of families, clinicians, and scientists in order to support individuals affected by NRXN1 disorder.
18
Lewisburg
-
Public Foundations
-
1500.
TNPO2 Foundation
TNPO2 FOUNDATION WORKED TO ACCELERATE ACCESS TO A CURE FOR ANY "N-OF-1" PATIENT.
Sacramento
PACIFIC NORTHWEST RESEARCH INSTITUTE
PNRI unravels the powerful mysteries of genetics to drive future medical breakthroughs.
492
SEATTLE
-
Alliance/Advocacy Organizations
-
1502.
GENERATION PATIENT INC
Generation Patient facilitates events, online programs, and advocacy initiatives for young adults with chronic and rare conditions to ensure they have the opportunities and resources to thrive.
575
GREENWOOD
-
Promotion of Business (Chambers of Commerce)
-
1503.
THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS INC
The American Society for Experimental Neurotherapeutics (ASENT): Where Industry, Academia, Patients & Gov't gather to advance development of CNS therapies.
77
HADDONFIELD


